BIOVIT — Bio Vitos Pharma AB Income Statement
0.000.00%
Last trade - 00:00- SEK5.33m
- SEK5.31m
- SEK0.41m
Annual income statement for Bio Vitos Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.307 | 1.12 | 1.32 | 3 | 0.411 |
| Cost of Revenue | |||||
| Gross Profit | 2.9 | 3.52 | 4.74 | 3 | -2.34 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 12 | 15.1 | 16.3 | 15.9 | 20.3 |
| Operating Profit | -11.7 | -14 | -14.9 | -12.9 | -19.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -11.7 | -14 | -14.9 | -12.9 | -19.9 |
| Net Income After Taxes | -11.7 | -14 | -14.9 | -12.9 | -19.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -11.7 | -14 | -14.9 | -12.9 | -19.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -11.7 | -14 | -14.9 | -12.9 | -19.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -6.05 | -5.93 | -5.71 | -2.3 | -4.52 |
| Dividends per Share |